Novel KV7 channel opener works well for focal epilepsy

a day ago
Jairia Dela Cruz
Jairia Dela CruzSenior Medical Writer; MIMS
Jairia Dela Cruz
Jairia Dela Cruz Senior Medical Writer; MIMS
Novel KV7 channel opener works well for focal epilepsy

Treatment with the potent KV7 channel opener azetukalner reduces seizure frequency, with rapid and durable effects, in patients with drug-resistant focal epilepsy, as shown in the phase III X-TOLE2 study.

Over the 12-week treatment period, azetukalner was associated with a significant, dose-dependent reduction in median monthly focal seizure frequency compared with placebo: −34.5 percent in the 15-mg azetukalner group and −53.2 percent in the 25-mg group vs −10.4 percent in the placebo group (p<0.001). [JAMA Neurol 2026;doi:10.1001/jamaneurol.2026.4141]

The median percentage reductions in seizure frequency observed with azetukalner vs placebo represent some of the largest decreases reported to date in patients with drug-resistant epilepsy, according to first study author Dr Jacqueline French from the New York University Grossman School of Medicine and NYU Langone Health, New York, New York, US, and colleagues. [Neurology 2016;87:314-323; Neurology 2012;79:589-596; Lancet Neurol 2020;19:38-48]

French and colleagues noted that the dose-dependent reduction in seizure frequency was evident as early as 1 week after treatment initiation, including a statistically significant improvement in seizure frequency in the 25-mg azetukalner group vs the placebo group that increased throughout the treatment period, resulting in a weekly median percentage change of −70.4 percent at week 12.

The proportions of patients who achieved 100-percent seizure reduction—defined as the complete absence of any countable focal seizures from the first day of treatment—were 6.5 percent in the azetukalner 25-mg group and 4 percent in the 15-mg group vs 0.8 percent in the placebo group (p=0.03 and p=0.12, respectively).

“Collectively, these findings highlight that azetukalner may both confer rapid seizure reduction and enable sustained, clinically meaningful seizure freedom over time,” French and colleagues said.

In terms of safety, azetukalner was generally well tolerated, with findings comparable to those of the phase IIb X-TOLE trial and no new safety signals identified, they noted. [JAMA Neurol 2023;80:1145-1154]

The most common treatment-emergent adverse events (TEAEs) were dizziness, somnolence, headache, and fatigue, consistent with central nervous system adverse events commonly associated with antiseizure mediations (ASMs), as the authors pointed out. The incidence of serious TEAEs were low and included dysarthria, tremor, confusional state, and fall, all of which occurred in the 25-mg azetukalner group. TEAEs led to treatment discontinuation in <10 percent of patients treated with azetukalner. There were no deaths reported.

“These findings support azetukalner, a novel KV7 channel opener, as a highly effective next-generation ASM that may help advance patient care by expanding therapeutic options available to improve the lives of people with epilepsy,” French and colleagues said.

“Azetukalner demonstrates characteristics that will be very beneficial in the clinic when approved. Rapid onset of seizure control is important in epilepsy treatment, and several effective therapies are limited by the requirement for slow titration and delayed onset of effect,” they continued.

Furthermore, the novel mechanism of action of azetukalner makes it a viable add-on therapy, considering the broad spectrum of concomitant ASMs X-TOLE2 patients were using during the study, the authors added.

X-TOLE2 included 374 adults (mean age 40 years, 50.8 percent female) with focal epilepsy experiencing ≥4 focal seizures per month despite stable treatment with up to three ASMs. These patients were randomly assigned to receive treatment with azetukalner at 15 mg (n=125) or 25 mg (n=124) or placebo (n=125). Treatment was taken orally once daily with the evening meal for 12 weeks with no titration period.

At baseline, the patients had a median of 12.75 focal seizures per month and had previously tried and stopped a median of five ASMs. Most patients (89.8 percent) were receiving 2–3 concomitant ASMs.